A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

Study Summary

The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.

Conditions

Charcot-Marie-Tooth Disease, Type 1A

Interventions / Drugs

EDK060, dose A EDK060, dose B EDK060, dose C EDK060, dose D Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment28 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151695+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.